BridgeBio Pharma Inc R&D Day Transcript
(presentation)
Thank you all for taking the time to join us today. For those of you that saw that video, there are several important pieces of context in there. We're going to be talking about the R&D that animates us here at BridgeBio. But it's really only important inasmuch as it helps us to serve patients with genetic disease. Elliott, who we've spoken about before, suffers from MOCD Type A. And I'm grateful to say that we have filed and had accepted for priority review by the FDA, or NDA, for that disease. And my hope is, with your support and through repeated application of our R&D engine over the course of the coming years, that Elliott is the first of hundreds of thousands of potentially millions of patients that we can help together.
The second piece of context actually relates to that number, hundreds of thousands or millions. From the get-go of BridgeBio, our ambition has been one of scale and growth. It is not to say that we just want to progress the last couple of products in our pipeline to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
